Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Current Leases (2020 - 2025)

Precision Biosciences (DTIL) has disclosed Current Leases for 6 consecutive years, with $1.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Leases rose 14.35% to $1.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.5 million, a 14.35% increase, with the full-year FY2024 number at $1.3 million, up 16.5% from a year prior.
  • Current Leases was $1.5 million for Q3 2025 at Precision Biosciences, up from $1.4 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $2.5 million in Q2 2023 to a low of $1.1 million in Q4 2023.
  • A 5-year average of $1.7 million and a median of $1.7 million in 2022 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: increased 29.68% in 2023, then crashed 51.06% in 2024.
  • Precision Biosciences' Current Leases stood at $1.8 million in 2021, then dropped by 7.9% to $1.7 million in 2022, then plummeted by 32.48% to $1.1 million in 2023, then rose by 16.5% to $1.3 million in 2024, then increased by 10.45% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Current Leases are $1.5 million (Q3 2025), $1.4 million (Q2 2025), and $1.4 million (Q1 2025).